•
Jul 05, 2020

Revvity Q2 2020 Earnings Report

PerkinElmer's Q2 2020 performance was driven by strong revenue growth and EPS, reflecting the company's resilience and the diversity of its business.

Key Takeaways

PerkinElmer reported a strong second quarter with a 12% increase in revenue to $811.7 million and a GAAP EPS of $1.23. Adjusted EPS was $1.57. The Diagnostics segment saw substantial growth, offsetting a decline in the Discovery & Analytical Solutions segment.

Revenue reached $811.7 million, representing a 12% reported growth and 13% organic growth.

GAAP EPS from continuing operations was reported at $1.23.

Adjusted EPS reached $1.57, compared to $1.00 in the second quarter of 2019.

Operating income from continuing operations was $175.6 million, with an operating profit margin of 21.6%.

Total Revenue
$812M
Previous year: $723M
+12.3%
EPS
$1.57
Previous year: $1
+57.0%
Organic Revenue Growth
13%
Gross Profit
$447M
Previous year: $348M
+28.6%
Cash and Equivalents
$219M
Previous year: $150M
+45.7%
Free Cash Flow
$122M
Previous year: $30.3M
+302.8%
Total Assets
$6.63B
Previous year: $6.4B
+3.7%

Revvity

Revvity

Revvity Revenue by Segment

Forward Guidance

The Company forecasts GAAP revenue in the range of $760 million to $860 million, GAAP earnings per share from continuing operations of $0.85 to $1.20 and, on a non-GAAP basis, adjusted earnings per share of $1.18 to $1.53 for the third quarter of 2020.

Revenue & Expenses

Visualization of income flow from segment revenue to net income